This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
NOVO NORDISK : Q1 beat; guidance upgrade but sentiment nonetheless dampened by price reductions Alphavalue
Top Midday Stories: Novo Nordisk, Linde Shares Fall Post-Earnings; Peloton Shares Plummet After Announcing Job Cuts, CEO Change; Exxon-Pioneer Deal Gets FTC Approval With One Caveat MT
Global markets live: Etsy, Qualcomm, Carvana, Rio Tinto, Apple... Our Logo
European Equities Traded in the US as American Depositary Receipts Rise Modestly Higher in Thursday Trading MT
News Highlights : Top Company News of the Day - Thursday at 11 AM ET DJ
News Highlights : Top Company News of the Day - Thursday at 9 AM ET DJ
Novo Nordisk Lifts Full-Year Sales Outlook as Obesity, Diabetes Drugs Drive First-Quarter Topline Beat MT
Novo Nordisk: Wegovy, Ozempic prices in US fell in Q1 RE
NOVO NORDISK : Gets a Buy rating from Barclays ZD
NOVO NORDISK : UBS gives a Neutral rating ZD
News Highlights : Top Company News of the Day - Thursday at 7 AM ET DJ
Novo Nordisk A/S Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Novo Nordisk Q1 Earnings, Net Sales Climb MT
Transcript : Novo Nordisk A/S, Q1 2024 Earnings Call, May 02, 2024
NOVO NORDISK : JP Morgan gives a Buy rating ZD
North American Morning Briefing : Stock Futures Rise as More Earnings Roll In DJ
MORNING BID AMERICAS-Fed QT taper calms the horses, yen pops again RE
Novo Nordisk: EPS up 29% in Q1 CF
NOVO NORDISK : Receives a Sell rating from Jefferies ZD
News Highlights : Top Company News of the Day - Thursday at 5 AM ET DJ
European Midday Briefing : Stocks Steady as Powell Suggests Rate Hike Unlikely DJ
Obesity drug maker Novo Nordisk lifts outlook again RE
NOVO NORDISK CFO: WE STILL EXPECT THE CATALENT DEAL TO CLOSE… RE
Novo Nordisk will continue to manage Wegovy starter doses, CFO says RE
NOVO NORDISK CFO: HAS LAUNCHED WEGOVY IN CANADA, WILL SOON LAUNC… RE
Chart Novo Nordisk A/S
More charts
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
897.7 DKK
Average target price
904.2 DKK
Spread / Average Target
+0.72%
Consensus
  1. Stock Market
  2. Equities
  3. NOVO B Stock
  4. News Novo Nordisk A/S
  5. Novo Nordisk in Talks to Acquire Controlling Stake in Biocorp